13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001587114
Total reported value
$2.1B
$2.1B
29 檔
84.9%
In Q1 2026, EcoR1 Capital, LLC's U.S. equity holdings reached a combined market value of $2.1B, distributed across 29 disclosed stock positions.
EcoR1 Capital, LLC executed strategic sector rebalancing during Q1 2026, establishing 10 new positions while fully exiting 9 holdings and trimming 4 positions.
In terms of portfolio concentration, the top 5 core holdings (including ZYME, ANAB, JAZZ) accounted for 84.9% of total reported equity market value during Q1 2026.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | ZYME | Zymeworks Inc | Stock-Other | 24.41% | +4.78% | — | |
| 2 | ANAB | Anaptysbio Inc | Stock-Other | 18.55% | +7.31% | — | |
| 3 | JAZZ | Jazz Pharmaceuticals plc | Stock-Healthcare | 13.69% | -13.69% | EXIT | |
| 4 | 260 | Centessa Pharmaceuticals-adr | Stock-Other | 10.81% | -10.81% | EXIT | |
| 5 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 6.61% | -6.61% | EXIT | |
| 6 | AKTS | Aktis Oncology Inc | Stock-Other | 3.66% | +3.90% | — | |
| 7 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 3.62% | -0.08% | — | |
| 8 | CGON | Cg Oncology Inc | Stock-Other | 3.17% | +3.93% | +3.49% | |
| 9 | CRSP | CRISPR Therapeutics AG | Stock-Healthcare | 2.80% | +0.88% | — | |
| 10 | ETON | Eton Pharmaceuticals Inc | Stock-Other | 2.27% | +1.55% | +6.96% | |
| 11 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 2.12% | +0.31% | — | |
| 12 | XNCR | Xencor Inc | Stock-Other | 1.12% | -1.12% | EXIT | |
| 13 | NGNE | Neurogene Inc | Stock-Other | 1.09% | +0.85% | — | |
| 14 | BBOT | Bridgebio Oncology Therapeut | Stock-Other | 1.07% | -0.02% | — | |
| 15 | MBX | Mbx Biosciences Inc | Stock-Other | 0.98% | +0.06% | -63.41% | |
| 16 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.80% | -0.17% | — | |
| 17 | ZBIO | Zenas Biopharma Inc | Stock-Other | 0.66% | +0.31% | — | |
| 18 | ERAS | Erasca Inc | Stock-Other | 0.62% | -0.33% | — | |
| 19 | EIKN | Eikon Therapeutics Inc | Stock-Other | 0.33% | +0.13% | — | |
| 20 | REPL | Replimune Group Inc | Stock-Other | 0.32% | -0.32% | EXIT | |
| 21 | ✓ | Zura Bio LTD | Stock-Other | 0.30% | +0.04% | — | |
| 22 | PHAT | Phathom Pharmaceuticals Inc | Stock-Other | 0.29% | +0.04% | — | |
| 23 | MREO | Mereo Biopharma Group Pl-adr | Stock-Other | 0.19% | -0.17% | +70.16% | |
| 24 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.14% | +1.03% | — | |
| 25 | PRLD | Prelude Therapeutics Inc | Stock-Other | 0.14% | -0.14% | EXIT | |
| 26 | IBIO | Ibio Inc | Stock-Other | 0.13% | -0.13% | EXIT | |
| 27 | ✓ | Helix Acquisition CORP Iii | Stock-Other | 0.09% | +0.01% | — | |
| 28 | ATRA | Atara Biotherapeutics Inc | Stock-Other | 0.02% | +0.85% | -82.62% | |
| 29 | SRZNW | Surrozen Inc-cw25 | Stock-Other | 0.01% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | 260 | Centessa Pharmaceuticals-adr | +7.3% | +105.80% | Add |
| 2 | AKTS | Aktis Oncology Inc | +3.7% | NEW | New buy |
| 3 | ANAB | Anaptysbio Inc | +1.2% | — | Unchanged |
| 4 | CGON | Cg Oncology Inc | +1.2% | +3.49% | Add |
| 5 | ORIC | Oric Pharmaceuticals Inc | +1.1% | — | Unchanged |
| 6 | RLAY | Relay Therapeutics Inc | +0.8% | NEW | New buy |
| 7 | ETON | Eton Pharmaceuticals Inc | +0.7% | +6.96% | Add |
| 8 | ERAS | Erasca Inc | +0.6% | NEW | New buy |
| 9 | JAZZ | Jazz Pharmaceuticals plc | +0.5% | — | Unchanged |
| 10 | EIKN | Eikon Therapeutics Inc | +0.3% | NEW | New buy |
| 11 | REPL | Replimune Group Inc | +0.3% | NEW | New buy |
| 12 | ✓ | Zura Bio LTD | +0.3% | NEW | New buy |
| 13 | PHAT | Phathom Pharmaceuticals Inc | +0.3% | NEW | New buy |
| 14 | STOK | Stoke Therapeutics Inc | +0.1% | NEW | New buy |
| 15 | PRLD | Prelude Therapeutics Inc | +0.1% | NEW | New buy |
| 16 | ✓ | Helix Acquisition CORP Iii | +0.1% | NEW | New buy |
| 17 | MREO | Mereo Biopharma Group Pl-adr | 0% | +70.16% | Add |
| 18 | SRZNW | Surrozen Inc-cw25 | 0% | — | Unchanged |
| 19 | IBIO | Ibio Inc | -0.1% | -28.95% | Trim |
| 20 | CAMP | Camp4 Therapeutics CORP | -0.1% | EXIT | Sold out |
| 21 | NGNE | Neurogene Inc | -0.1% | — | Unchanged |
| 22 | EOLS | Evolus Inc | -0.2% | EXIT | Sold out |
| 23 | LKFT | Lakefront Biotherapeutic-adr | -0.4% | — | Unchanged |
| 24 | NUVB-WS | Nuvation Bio Inc -cw27 | -0.4% | EXIT | Sold out |
| 25 | MNKD | Mannkind CORP | -0.4% | EXIT | Sold out |
| 26 | ATRA | Atara Biotherapeutics Inc | -0.5% | -82.62% | Trim |
| 27 | CRSP | CRISPR Therapeutics AG | -0.5% | — | Unchanged |
| 28 | BBOT | Bridgebio Oncology Therapeut | -0.5% | — | Unchanged |
| 29 | ZBIO | Zenas Biopharma Inc | -0.6% | — | Unchanged |
| 30 | VYGR | Voyager Therapeutics Inc | -0.7% | EXIT | Sold out |
| 31 | AQST | Aquestive Therapeutics Inc | -0.8% | EXIT | Sold out |
| 32 | PCVX | Vaxcyte Inc | -0.9% | EXIT | Sold out |
| 33 | GPCR | Structure Therapeutics Inc | -1.1% | EXIT | Sold out |
| 34 | XNCR | Xencor Inc | -1.2% | -34.22% | Trim |
| 35 | MBX | Mbx Biosciences Inc | -2.1% | -63.41% | Trim |
| 36 | CRNX | Crinetics Pharmaceuticals In | -2.5% | — | Unchanged |
| 37 | IMNM | Immunome Inc | -2.8% | EXIT | Sold out |
| 38 | ZYME | Zymeworks Inc | -3% | — | Unchanged |
According to official SEC Form 13F filings, EcoR1 Capital, LLC reported a total U.S. public equity portfolio value of $2.1B across 29 disclosed positions in Q1 2026.
During Q1 2026, EcoR1 Capital, LLC's top holdings by market value included ZYME (24.4%)、ANAB (18.6%)、JAZZ (13.7%). The largest single position, ZYME, represented 24.4% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Top New Position Initiated
AKTS
市值: $86.3M
Top Position Liquidated / Trimmed
IMNM
前期市值: $61.3M
In Q1 2026, EcoR1 Capital, LLC made 27 total portfolio adjustments, initiating 10 new buys, adding to 4 positions, trimming 4 holdings, and fully liquidating 9 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.